title: [Statins in the treatment of polycystic ovary syndrome].
abstract: Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 6-9% of women in reproductive age. It is characterized by hyperandrogenism, oligo- or anovulation and infertility PCOS is associated with important cardiovascular risk factors including: obesity dyslipidemia, systemic inflammation and endothelial dysfunction. Statins are well-tested medications reducing a broad range of cardiovascular risk factors. The primary mode of action of statins is inhibition of HMG-Co A reductase, a rate-limiting step of cholesterol synthesis. In recent randomized studies in PCOS women, statins have decreased testosterone level, improved menstrual cycle regularity and lipid profile.
authors.affiliation: Klinika Niepłodności i Endokrynologii Rozrodu, Katedra Ginekologii i Potoznictwa i Onkologii Ginekologicznej, Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu. banaszewska@gpsk.am.poznan.pl
authors.forename: Beata
authors.initials: B
authors.lastname: Banaszewska
authors.forename: Robert
authors.initials: R
authors.lastname: Spaczyński
authors.forename: Leszek
authors.initials: L
authors.lastname: Pawelczyk
mesh_terms: D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008597:Menstrual Cycle / Q000187:drug effects; D010053:Ovary / Q000187:drug effects*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013739:Testosterone / Q000378:metabolism; D016387:Women's Health
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013739:Testosterone